Contrasting Guided Therapeutics (OTCMKTS:GTHP) & EssilorLuxottica (OTCMKTS:ESLOY)

EssilorLuxottica (OTCMKTS:ESLOY) and Guided Therapeutics (OTCMKTS:GTHP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares EssilorLuxottica and Guided Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EssilorLuxottica	N/A	N/A	N/A
Guided Therapeutics	N/A	N/A	-274.24%

Risk & Volatility

EssilorLuxottica has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of EssilorLuxottica shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 66.8% of Guided Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares EssilorLuxottica and Guided Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EssilorLuxottica	$32.23 billion	2.86	$2.62 billion	N/A	N/A
Guided Therapeutics	$770,000.00	25.08	-$3.20 million	($0.04)	-5.00

EssilorLuxottica has higher revenue and earnings than Guided Therapeutics.

Analyst Recommendations

This is a summary of current recommendations and price targets for EssilorLuxottica and Guided Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EssilorLuxottica	0	2	5	2	3.00
Guided Therapeutics	0	0	0	0	0.00

Summary

EssilorLuxottica beats Guided Therapeutics on 7 of the 10 factors compared between the two stocks.

About EssilorLuxottica

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.